Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL OLE: Long-term Infigratinib in Children with Achondroplasia
2021-001855-15Phase 2Active
- Sponsor
- QED Therapeutics
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of infigratinib in achondroplasia (ACH), sponsored by QED Therapeutics. Primary endpoint: Safety and tolerability of long-term infigratinib. Started Sep 2021; status: active.
02
Drugs
infigratinib
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2021-001855-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001855-15.